A compound traditional Chinese medicine for treating gastric precancerous lesions and preparation method thereof

By preparing compound Chinese medicine containing a variety of Chinese medicine ingredients, combined with wet powder granulation method, the problem of failure to effectively remove blood stasis and strengthen the spleen and stomach in the prior art was solved, and the treatment effect of chronic atrophic gastritis was significantly improved.

CN117045762BActive Publication Date: 2024-11-15INNER MONGOLIA MEDICAL UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202311237212.7
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-09-22
Publication Date
2024-11-15
Estimated Expiration
2043-09-22

AI Technical Summary

Technical Problem

The existing compound traditional Chinese medicine technology fails to effectively remove blood stasis and strengthen the spleen and stomach when treating chronic atrophic gastritis precancerous lesions, resulting in poor efficacy and uncertain efficacy of Western medicine regimens.

Method used

Provide a compound Chinese medicine, including Salvia miltiorrhiza, Amomum villosa, Atractylodes, Yuanhu, Magnolia officinalis, Curcuma zedo, Puhuang, Centipede, Centipede, Centipede, Centipede, Centipede, Chicken Gin, and White Flower Snake Tongue, which is granulated by wet powder Prepare pills or decoctions to remove blood stasis and unblock the meridians and strengthen the spleen and stomach.

Benefits of technology

This compound Chinese medicine significantly improves the symptoms of precancerous gastric lesions, such as stomach pain, bloating, stomach acid, black stool, etc. It has significant efficacy and no side effects. It improves the therapeutic effect through the dual effects of removing blood stasis and unblocking the meridians and strengthening the spleen and stomach.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN117045762B_ABST
    Figure CN117045762B_ABST
Patent Text Reader

Abstract

The invention discloses a compound Chinese medicine for treating gastric precancerous lesions and a preparation method, and belongs to the field of medical technology. The compound Chinese medicine includes: 5-15 parts of salvia miltiorrhiza, 3-10 parts of amomum, 6-12 parts of atractylodes, 3-12 parts of corydalis, 3-12 parts of magnolia bark, 3-15 parts of curcuma, 3-10 parts of pollen, 3-5 parts of centipede, 3-10 parts of honeycomb, 3-10 parts of galangal, 9-30 parts of pseudostellaria, 15-60 parts of chicken gizzard lining and 15-60 parts of oldenlandia diffusa. The compound Chinese medicine of the present invention has reasonable compatibility, is safe and effective, and has been clinically verified for many years, mainly for removing blood stasis and dredging collaterals, and taking into account the spleen and stomach strengthening and strengthening the body, and has remarkable curative effect; the preparation method of the present invention is simple to operate and practical, and the dosage form prepared according to the preparation method of the present invention can be completely absorbed by oral administration into the body, has high bioavailability, and is easy to divide into doses, convenient to take, has good oral compliance, high safety, and remarkable curative effect.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the technical field of medicine, and in particular to a compound traditional Chinese medicine for treating gastric precancerous lesions and a preparation method thereof. Background Art

[0002] "The spleen and stomach are the foundation of the acquired constitution", and are also the "source of qi and blood biochemical transformation", and "internal damage to the spleen and stomach will cause all kinds of diseases". Therefore, the occurrence of chronic atrophic gastritis is closely related to the weakness and dysfunction of the spleen and stomach. When the spleen and stomach are weak and dysfunctional, it will affect the transformation of water and grain essence, on this basis, leading to insufficient qi and blood, low organ function, and muscle tendons and veins being malnourished, which will eventually lead to atrophy. Moreover, the development of this disease is a chronic and protracted process. It will experience the transformation process of qi deficiency, qi stagnation, phlegm obstruction, and blood stasis in the pathological opportunity, and will experience the progression process of chronic atrophic gastritis, intestinal metaplasia, dysplasia, and cancer in pathology. Among them, the formation of blood stasis is the key link in the canceration of chronic atrophic gastritis. Blood stasis takes into account the dual identities of pathological products and pathogenic factors. First of all, qi deficiency, qi stagnation, and phlegm obstruction will lead to blood stasis. In turn, blood stasis will aggravate the severity of qi deficiency, qi stagnation, and phlegm obstruction. This forms a vicious circle, pushing the disease to become serious and worse. Therefore, the key to treating precancerous lesions of chronic atrophic gastritis lies in removing blood stasis while strengthening the spleen and stomach.

[0003] Most of the existing technical solutions of compound Chinese medicines are treated from the perspectives of regulating qi, strengthening the body, removing dampness and heat, and neither grasp the key pathogenesis of blood stasis nor achieve balancing blood stasis and strengthening the body. This is why the existing technical solutions of compound Chinese medicines in society are not effective in treating precancerous lesions of chronic atrophic gastritis. In addition, the existing technical solutions of Western medicines are mainly based on regular follow-up and improving dietary structure, and are coordinated to eradicate Hp, non-steroidal drugs (NSAIDs), supplement trace elements, folic acid, etc., but their definite efficacy is still uncertain. For this reason, the present invention provides a compound Chinese medicine for safely and effectively treating precancerous lesions of gastric cancer (PLGC). Summary of the invention

[0004] The purpose of the present invention is to provide a compound Chinese medicine for treating gastric precancerous lesions and a preparation method thereof, so as to solve the problems existing in the above-mentioned prior art. The compound Chinese medicine prepared by the present invention has reasonable compatibility, is safe and effective, has been clinically verified for many years, and mainly functions as removing blood stasis and dredging collaterals, while also taking into account strengthening the spleen and stomach and restoring the body, and has a significant effect in treating gastric precancerous lesions.

[0005] To achieve the above object, the present invention provides the following solutions:

[0006] The invention provides a compound Chinese medicine for treating gastric precancerous lesions. The raw materials of the compound Chinese medicine comprise, by weight, 5-15 parts of salvia miltiorrhiza, 3-10 parts of amomum villosum, 6-12 parts of atractylodes macrocephala, 3-12 parts of corydalis, 3-12 parts of magnolia bark, 3-15 parts of curcuma, 3-10 parts of pollen, 3-5 parts of centipede, 3-10 parts of honeycomb, 3-10 parts of soapberry, 9-30 parts of pseudoginseng, 15-60 parts of chicken gizzard lining and 15-60 parts of oldenlandia diffusa.

[0007] Furthermore, the raw materials of the compound Chinese medicine include, by weight: 12 parts of Salvia miltiorrhiza, 10 parts of Amomum villosum, 10 parts of Atractylodes macrocephala, 12 parts of Corydalis yanhusuo, 12 parts of Magnolia officinalis, 10 parts of Curcuma zedoaria, 10 parts of Pollen Typhae, 4 parts of Scolopendra subspinipes, 10 parts of Beehive, 10 parts of Gleditsia sinensis, 15 parts of Pseudostellaria pseudoginseng, 15 parts of Gallus gallus domestica and 15 parts of Hedyotis diffusa.

[0008] Furthermore, the dosage form of the compound Chinese medicine includes pills and decoctions.

[0009] Furthermore, the pills include water pills and honey pills.

[0010] Furthermore, the gastric precancerous lesions include gastric precancerous lesions of chronic atrophic gastritis with gastric collateral stasis type.

[0011] The present invention also provides a method for preparing the compound Chinese medicine, comprising the following steps:

[0012] The weighed raw materials are crushed into powder, the powder is made into granules by wet powder granulation and molding method, water is sprayed on the powder particles to moisten them, powder is sprinkled for absorption, the operation is repeated to obtain uniform pellets, and finally the pellets are covered, dried and coated;

[0013] Alternatively, part of the weighed raw materials are crushed into powder, the powder is made into granules by wet powder granulation and molding method, the powder particles are sprayed with medicine juice made from the remaining raw materials to moisten them, and the powder is sprinkled for absorption, the operation is repeated to obtain uniform pellets, and finally the pellets are covered, dried and coated.

[0014] Furthermore, some of the raw materials include pollen, centipede, beehive, chicken gizzard lining and soapberry; the medicinal juice is the medicinal juice obtained by decocting salvia miltiorrhiza, amomum villosum, atractylodes macrocephala, corydalis, magnolia bark, curcuma, pseudostellaria and oldenlandia diffusa.

[0015] The present invention also provides a method for preparing the compound Chinese medicine, comprising the following steps:

[0016] Mix the weighed raw materials, add water and soak for 30 to 40 minutes, boil over high heat for 40 to 50 minutes for the first time; add water and boil over low heat for 30 to 40 minutes for the second time; add water and boil over low heat for 20 to 30 minutes for the third time; combine the medicinal liquids obtained in the three times.

[0017] The present invention also provides a method for preparing the compound Chinese medicine, comprising the following steps:

[0018] Weigh the raw materials, dry and crush them, mix the obtained powder with refined honey to adjust the medicine, roll them into strips, make them into pills, and then package them.

[0019] Furthermore, the mass ratio of the medicinal powder to the honey is 1:(1.2-1.5).

[0020] The present invention discloses the following technical effects:

[0021] The combination of various drugs in this compound has the effects of promoting blood circulation and removing blood stasis, promoting qi and relieving pain, breaking blood and eliminating symptoms, attacking toxins and dispersing nodules, removing blood stasis and unblocking collaterals, strengthening the spleen and stomach, removing dampness and promoting diuresis, and replenishing qi and nourishing essence. It has a significant therapeutic effect on gastric precancerous lesions, especially stomach pain, bloating, gastric acid, black stools, etc., with high efficiency and no side effects. The white atractylodes in the prescription is warm in nature, bitter and sweet in taste, and can nourish the spleen and replenish qi, dry dampness and promote diuresis. It is the first medicine for spleen qi tonification. "Ben Cao Tong Xuan" states that "Atractylodes macrocephala is a medicine for nourishing the spleen and stomach, and there is no better medicine than it. When the earth is strong, it can promote movement, so those who cannot eat, those who have food stagnation, and those who have lumps and accumulation can all use it. When the earth is strong, it can overcome dampness, so those who suffer from phlegm and fluid, swelling, and dampness all rely on it. When the earth is strong, the clear air is good at rising, and the essence is sent up, the turbid air is good at descending, and the dregs are sent down, so those who vomit and diarrhea cannot be missing it." This medicine is sweet and can nourish the deficiency, and bitter and can purge the excess, playing an important role in the treatment of this disease. Curcuma zedoaria is pungent and bitter, warm in nature, and belongs to the liver and spleen meridians, with the function of promoting qi and breaking blood. Zhang Xichun once said that the two medicines of Curcuma zedoaria "are good at breaking blood, especially good at regulating qi... those with stasis can slowly eliminate it, and even those without stasis can also use its circulation power to remove the stagnation of tonic medicine... when used together with ginseng, turbidity, and astragalus, it can greatly stimulate appetite and promote eating." ("Ten-Quan Yuzhen Decoction for Treating Yin Deficiency and Fatigue") Atractylodes macrocephala nourishes the spleen and stomach, Curcuma zedoaria breaks blood and eliminates symptoms, promotes qi and relieves pain. Both enter the spleen meridian and are the main medicine, playing the role of strengthening the spleen and promoting blood circulation. Salvia miltiorrhiza tastes bitter and can purge, nourish blood and promote blood circulation. There is a saying that Salvia miltiorrhiza has the same function as the four herbs. It can promote blood circulation and remove blood stasis without hurting the body. Pollen puhuang tastes sweet and is mild in nature. It belongs to the liver and pericardium meridians and can stop bleeding and remove blood stasis. Salvia miltiorrhiza and Pollen puhuang are good at promoting blood circulation and removing blood stasis. They are combined with Shixiao Powder and Salvia miltiorrhiza Drink, so they are the minister medicines to assist the main medicine. Magnolia officinalis is bitter, pungent and warm. It enters the spleen, stomach, lung and large intestine meridians. It can dry dampness and eliminate phlegm, reduce qi and eliminate fullness, and disperse dampness and fullness in the spleen and stomach. Corydalis yanhusuo is pungent, bitter and warm. It belongs to the liver and spleen meridians. It can remove qi stagnation in blood circulation, make qi smooth and blood regulated, and is a good analgesic. Magnolia officinalis and Corydalis play the role of regulating qi, and Corydalis can promote blood circulation, remove blood stasis, and relieve pain; Hedyotis diffusa belongs to the stomach, large intestine, and small intestine meridians, and has the effects of clearing heat, detoxifying, and reducing swelling. Beehives are flat in nature, sweet in taste, and belong to the stomach meridian. They can attack poisons and kill insects, dispel wind and relieve pain. Modern research shows that beehives have antibacterial, anti-tumor, and anti-inflammatory effects. Precancerous lesions and polyps of the stomach are caused by accumulation of heat and toxicity, retention of phlegm and dampness, and blood stasis and qi stagnation. They are treated with the method of clearing heat, detoxifying, removing dampness, and promoting blood circulation. Hedyotis diffusa and beehives can directly break the heat and toxicity, and can eliminate phlegm and dampness condensation. The above six herbs are all ministerial drugs. Sophora flavescens is pungent and warm in nature, and belongs to the liver, stomach, and lung meridians. It can be used to reduce swelling and pus with its sharp thorns, and eliminate toxins and attack poisons; Scolopendra subspinipes is pungent, warm, and toxic, and enters the liver meridian. It can dredge the meridians and relieve pain, attack toxins and disperse knots. It is toxic and can disperse swelling and remove blood stasis, and it can help Hedyotis diffusa and Beehive to detoxify and reduce swelling, and dredge the meridians and remove blood stasis; Chicken gizzard lining is sweet and flat in nature, and belongs to the spleen, stomach, small intestine, and bladder meridians. It can strengthen the stomach and digest food, and protect the spleen and stomach; Amomum villosum is pungent in taste, warm in nature, and belongs to the spleen, stomach, and kidney meridians. It has the functions of removing dampness and promoting qi, and awakening the spleen and appetizing. In the clinical treatment of various chronic gastritis, the small dose of Amomum villosum is used according to the physiological characteristics and pathological changes of the stomach. It can harmonize the stomach and reduce adverse reactions, warm but not dry, and promote qi without breaking qi. It is an important medicine for awakening the spleen and stomach.Chronic atrophic gastritis is a long-term disease with many symptoms of weakness, and the blood vessels in the gastric mucosa are blocked, so Pseudostellariae Radix is ​​used to replenish qi and nourish the middle. It tastes sweet and slightly bitter, is neutral in nature, and enters the spleen and lung meridians. It replenishes qi and strengthens the spleen, replenishes qi and produces body fluid, and can assist the main medicine to play the effect of replenishing spleen and replenishing qi. The above five herbs are all adjuvants. The whole prescription has a mild taste, which aims to remove blood stasis and dredge collaterals, strengthen the spleen and nourish the essence, disperse the knots and eliminate, and remove accumulation without hurting the body.

[0022] The compound Chinese medicine for treating gastric precancerous lesions provided by the present invention has reasonable compatibility, is safe and effective, has been clinically verified for many years, mainly removes blood stasis and dredges collaterals, and takes into account strengthening the spleen and stomach, and has significant curative effect. The preparation method of the present invention is simple to operate and practical. The dosage form prepared according to the preparation method of the compound reduces the loss of effective ingredients, can be completely absorbed after oral administration into the body, has high bioavailability, and is easy to divide into doses, convenient to take, has good oral compliance, high safety, and significant curative effect. BRIEF DESCRIPTION OF THE DRAWINGS

[0023] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.

[0024] Figure 1 The figure is a process flow chart for preparing water pills;

[0025] Figure 2 The process flow chart of the preparation of improved water pills;

[0026] Figure 3 The figure is a process flow chart for preparing the decoction;

[0027] Figure 4 The figure is a process flow chart for preparing honey pills;

[0028] Figure 5 Gastroscopy report before treatment for typical case patients;

[0029] Figure 6 Gastroscopy report after treatment for typical case patients;

[0030] Figure 7 Pathological report of a typical case patient before treatment;

[0031] Figure 8 This is the pathology report of a typical case patient after treatment. DETAILED DESCRIPTION

[0032] Various exemplary embodiments of the present invention will now be described in detail. This detailed description should not be considered as limiting the present invention, but should be understood as a more detailed description of certain aspects, features, and embodiments of the present invention.

[0033] It should be understood that the terms described in the present invention are only for describing a particular embodiment and are not intended to limit the present invention. In addition, for the numerical range in the present invention, it should be understood that each intermediate value between the upper and lower limits of the scope is also specifically disclosed. The intermediate value in any stated value or stated range, and each smaller range between any other stated value or intermediate value in the described range is also included in the present invention. The upper and lower limits of these smaller ranges can be independently included or excluded in the scope.

[0034] Unless otherwise indicated, all technical and scientific terms used herein have the same meanings as those generally understood by those skilled in the art. Although the present invention describes only preferred methods and materials, any methods and materials similar or equivalent to those described herein may also be used in the implementation or testing of the present invention. All documents mentioned in this specification are incorporated by reference to disclose and describe the methods and / or materials associated with the documents. In the event of a conflict with any incorporated document, the content of this specification shall prevail.

[0035] It will be apparent to those skilled in the art that various modifications and variations may be made to the specific embodiments of the present invention description without departing from the scope or spirit of the present invention. Other embodiments derived from the present invention description will be apparent to those skilled in the art. The present invention description and examples are exemplary only.

[0036] The words “include,” “including,” “have,” “contain,” etc. used in this document are open-ended terms, meaning including but not limited to.

[0037] The Yellow Emperor's Classic of Internal Medicine records that "the disease lasts for a long time and goes deep, and the circulation of the Ying and Wei is blocked." In the Sui Dynasty, Chao Yuanfang mentioned in the Treatise on the Causes and Symptoms of Various Diseases that "the blood and qi are blocked and become lumps." Ye Tianshi said: "The disease is initially in the meridians, and the pain lasts for a long time and enters the collaterals, because the meridians are responsible for qi and the collaterals are responsible for blood." The present invention believes that "stasis" runs through the entire precancerous lesions of chronic atrophic gastritis, and the stasis of the stomach collaterals is the key pathogenesis of its occurrence and development.

[0038] The invention purpose of this compound Chinese medicine is to mainly target the formation of gastric precancerous lesions with blood stasis as the main pathogenesis, combined with pathological factors such as qi stagnation or phlegm dampness. Gastric precancerous lesions refer to intestinal metaplasia and dysplasia of the gastric mucosa, which are often secondary to chronic atrophic gastritis, and gastric precancerous lesions are more likely to develop into gastric cancer. This compound is mainly suitable for gastric precancerous lesions of chronic atrophic gastritis with gastric collateral stasis type. Gastric collateral stasis syndrome: Main symptoms: fullness or pain in the stomach. Secondary symptoms: ① Stomach pain that refuses to be pressed; ② Black stools; ③ Dark complexion. Tongue and pulse: The tongue is dark red or has petechiae and ecchymoses; the pulse is stringy and astringent.

[0039] Example 1

[0040] A compound traditional Chinese medicine for treating gastric precancerous lesions, comprising the following raw materials in parts by weight: 12 parts of salvia miltiorrhiza, 10 parts of amomum villosum, 10 parts of atractylodes macrocephala, 12 parts of corydalis, 12 parts of magnolia bark, 10 parts of curcuma, 10 parts of pollen, 4 parts of centipede, 10 parts of honeycomb, 10 parts of galangal, 15 parts of pseudostellaria, 15 parts of chicken gizzard lining and 15 parts of oldenlandia diffusa.

[0041] The preparation method of water pills is as follows:

[0042] Step 1, after the above-mentioned raw materials are processed and prepared as required, they are crushed, sieved and mixed to obtain fine powder of the medicine for standby use;

[0043] Step 2, demoulding: wet powder granulation demoulding method, the demoulding powder is made into granules, placed in a pan pill pan, and then rotated and rubbed to remove the edges and corners, and then sprayed with water to moisten, sprinkled with powder for absorption, and repeated many times. During the panning process, kneading, bumping, and turning operations are performed to gradually enlarge the pill mold into spherical small particles, and the oversized or undersized and irregular-shaped pill molds are sieved out and dissolved in the preparation water for later use;

[0044] Step 3, calculation method of pill mold quantity: First, divide the weight of the powder for this batch of pills (unit: grams) by 0.2 grams (the weight of a standard water pill), which is equal to the number of standard water pills that should be produced. Then use a balance to weigh 5 grams of wet molds to find out the number, divide 5 grams by this number to calculate the average weight of each pill mold, and then multiply the weight of each wet pill mold by the number of standard water pills that should be produced this time to get the amount of pill molds needed;

[0045] Step 4, molding: Alternately add water and drug powder to the qualified pill molds, and gradually enlarge them until they are close to the finished product. In this process, when the pills are large enough and not easy to stick together, the drug slurry water dissolved in the above preparations is used as an adhesive and sprayed on the panned pills, and they must not be discarded;

[0046] Step 5, pill selection: Use a medicine sieve to screen the pellets to obtain uniform pellets. Pellets that are too small should be enlarged, and those that are too large and deformed should be separated and dissolved in an appropriate amount of preparation water as a binder. Make the finished product uniform in size;

[0047] Step 6, covering: Appropriate materials (clean water, clear slurry or fine powder of medicine) are poured onto the screened qualified pellets to the size of finished products, so that the surface of the pellets is dense, smooth and uniform in color. Commonly used covering methods include dry powder covering, clean water covering, clear slurry covering, etc. This embodiment adopts dry powder covering;

[0048] Step 7, drying: After covering, the pellets are dried in time. The drying temperature is generally controlled below 80°C. Pills containing volatile or heat-sensitive ingredients should be dried below 60°C. The temperature is gradually increased during drying, and the pills are constantly turned over to avoid the formation of yin and yang sides. The drying temperature used in this embodiment is 60°C.

[0049] Step 8, coating and polishing: moisten the dried water pills with water, add coating materials and rotate to coat, then rotate and polish until the surface of the pills is moist and shiny, then take out and dry.

[0050] Figure 1 This is the process flow chart of water pill preparation.

[0051] Example 2

[0052] The preparation method of the improved water pill is as follows:

[0053] Step 1, weigh each raw material medicine described in Example 1, and process and prepare as required. In order to facilitate the preparation and fully retain the effective ingredients in the prescription, some raw materials are crushed, sieved, and mixed to obtain fine powder for standby use. The powdered medicinal materials include pollen, centipede, honeycomb, chicken gizzard lining and soapberry.

[0054] The prescriptions containing large amounts of fiber and effective ingredients that can be dissolved in water are designed to be prepared into a medicinal juice by a traditional decoction decoction method (refer to the preparation method of Example 3) for standby use. The medicinal juice is used as an excipient. The medicinal materials for decoction include salvia miltiorrhiza, amomum villosum, atractylodes macrocephala, corydalis yanhusuo, magnolia bark, zedoaria, pseudoginseng and hedyotis diffusa.

[0055] Step 2, demoulding: wet powder granulation demoulding method, the demoulding powder is made into granules, placed in a pan pill pot, and then rotated and rubbed to remove the edges and corners, and then sprayed with medicine juice to moisten, sprinkled with powder for absorption, and repeated many times. During the panning process, kneading, bumping, and turning operations are performed to gradually enlarge the pill mold into spherical small particles. The oversized, undersized, and irregular-shaped pill molds are sieved out and dissolved in the medicine juice for later use;

[0056] Step 3, calculation method of pill mold quantity: First, divide the weight of the powder for this batch of pills (unit: grams) by 0.2 grams (the weight of a standard water pill), which is equal to the number of standard water pills that should be produced. Then use a balance to weigh 5 grams of wet molds to find out the number, divide 5 grams by this number to calculate the average weight of each pill mold, and then multiply the weight of each wet pill mold by the number of standard water pills that should be produced this time to get the amount of pill molds needed;

[0057] Step 4, molding: Alternately add the drug juice and drug powder to the qualified pill molds, and gradually enlarge them to a size close to the finished product. In this process, when the pills are large enough and not easy to stick together, the drug slurry water dissolved in the drug juice of the above preparation is sprayed on the panned pills as an adhesive and shall not be discarded;

[0058] Step 5, pill selection: Use a medicine sieve to select uniform and consistent pills. The too small pills will be enlarged, and the oversized and deformed ones should be separated and dissolved in the preparation juice as the binder. Make the finished product uniform in size;

[0059] Step 6, covering: Appropriate materials (medicine solution, medicine slurry, fine powder of medicine) are spread on the screened qualified shaped pellets to the finished size, so that the surface of the pellets is dense, smooth and uniform in color. Commonly used covering methods include dry powder covering, medicine solution covering, medicine slurry covering, etc. This embodiment adopts dry powder covering;

[0060] Step 7, drying: After covering, the pellets are dried in time. The drying temperature is generally controlled below 80°C. Pills containing volatile or heat-sensitive ingredients should be dried below 60°C. The temperature is gradually increased during drying, and the pills are constantly turned over to avoid the formation of yin and yang sides. The drying temperature used in this embodiment is 60°C.

[0061] Step 8, coating and polishing: moisten the dried water pills with water, add coating materials and rotate to coat, then use rotary polishing to make the surface of the pills moist and shiny, then take them out and dry them.

[0062] Figure 2 This is a flow chart of the preparation process of improved water pills.

[0063] It was found in the experiment that the clinical dosage of the improved water pills was reduced to half of the traditional water pills prepared in Example 1, which improved the patient's compliance and was beneficial to improving the efficacy of the drug. At the same time, it had the characteristics of masking the bad smell of the drug and being easy to store and take.

[0064] Example 3

[0065] A compound traditional Chinese medicine for treating gastric precancerous lesions, comprising the following raw materials in parts by weight: 10 parts of salvia miltiorrhiza, 13 parts of amomum villosum, 6 parts of atractylodes macrocephala, 10 parts of corydalis, 3 parts of magnolia bark, 15 parts of zedoaria, 3 parts of pollen, 5 parts of centipede, 3 parts of honeycomb, 7 parts of galangal, 9 parts of pseudostellaria, 60 parts of chicken gizzard lining and 20 parts of oldenlandia diffusa.

[0066] Decoction preparation method:

[0067] Weigh and mix the raw materials according to weight, add 6 times the weight of water and soak for 30 minutes, boil for 50 minutes with high heat for the first time; add 4 times the weight of water and boil for 30 minutes with low heat for the second time; add 2 times the weight of water and boil for 20 minutes with low heat for the third time; combine the medicinal liquids obtained in the three times to obtain the compound Chinese medicine decoction for treating gastric precancerous lesions.

[0068] Figure 3 This is a process flow chart for the preparation of decoction.

[0069] Example 4

[0070] A compound traditional Chinese medicine for treating gastric precancerous lesions, comprising the following raw materials in parts by weight: 5 parts of salvia miltiorrhiza, 6 parts of amomum villosum, 12 parts of atractylodes macrocephala, 3 parts of corydalis, 8 parts of magnolia bark, 3 parts of curcuma, 7 parts of pollen, 3 parts of centipede, 4 parts of honeycomb, 3 parts of galangal, 30 parts of pseudostellaria, 15 parts of chicken gizzard lining and 60 parts of oldenlandia diffusa.

[0071] Preparation method of honey pills:

[0072] Weigh each raw material by weight, bake it over a low fire, and then use a powder grinder to make it into powder. Mix honey with the weight of the powder in a ratio of 1:1.5, and then boil the honey; mix the refined honey with the powder, roll it into strips, make pills, and package it.

[0073] Figure 4 This is a process flow chart for the preparation of honey pills.

[0074] Effect verification: Observation on the therapeutic effect of Weihe Huayu Pills in treating PLGC of gastric collateral stasis type

[0075] The water pill preparation prepared in Example 1 is called "Weihe Huayu Pills" (also known as Weihe IV).

[0076] 1Clinical data:

[0077] The cases selected for this study were 90 outpatient and inpatient patients who were diagnosed with PLGC by Western medicine and had gastric collateral stasis syndrome by TCM diagnosis at the Affiliated Mongolian Traditional Chinese Medicine Hospital of Inner Mongolia Medical University and the Inner Mongolia Autonomous Region Hospital of Traditional Chinese Medicine from June 2021 to September 2022.

[0078] 2Diagnostic criteria:

[0079] 2.1 Western medicine diagnostic criteria

[0080] Refer to the "Consensus on the Diagnosis and Treatment of Chronic Atrophic Gastritis with Integrated Traditional Chinese and Western Medicine" (2017) and the CAG diagnostic criteria (Trial) of the "Guidelines for Clinical Research of New Chinese Medicines".

[0081] (1) Gastroscopy diagnostic criteria:

[0082] ① Changes in mucosal color: During atrophy, the mucosal color is grayish white, grayish yellow, or gray; there is inconsistency in the depth of the mucosa in the same area, and the areas with strong red color also have grayish white. Generally, there may be slightly raised small red dots or erythema in the grayish yellow or grayish white areas; the range of atrophy may be diffuse, local, or focal, the mucosa becomes thinner and sunken, and the boundary is often not obvious.

[0083] ② Vascular visibility: Small blood vessels can be seen in the mucosa in the early stage of atrophy. In severe cases, dark red branch-like large blood vessels can be seen. The blood vessels at the gastric fundus and cardia can also be seen under normal circumstances.

[0084] ③ After atrophy, the glandular crypts may proliferate and elongate or undergo intestinal metaplasia, showing signs of overgrowth. The mucosal layer becomes thicker, and the blood vessels under the mucosa cannot be seen. The mucosal surface is rough and uneven, with granular or nodular stiffness.

[0085] (2) Pathological diagnostic criteria:

[0086] ① Atrophy of the intrinsic glands;

[0087] ②Thickening of the muscularis mucosa;

[0088] ③Intestinal metaplasia or pseudopyloric gland metaplasia;

[0089] ④Membrane propria inflammation;

[0090] ⑤ Lymph follicle formation.

[0091] (3) Disease classification standards

[0092] ① Grading standard for gastric mucosa endoscopic observation

[0093] Mild: Red and white, with white as the main color, and the vascular network is visible, often focal.

[0094] Moderate: Red and white, mainly white, with a clearly visible vascular network. Often diffuse, with flattened and shallow mucosal folds. Type B atrophy ranges from the antrum to the angle of the stomach.

[0095] Severe: In addition to the above manifestations, the mucosa is also granular or nodular. Type B atrophy extends to the middle and upper part of the stomach.

[0096] ② Pathological histological grading standard of glandular atrophy

[0097] Mild: The intrinsic glands are reduced by less than 1 / 3;

[0098] Moderate: The intrinsic glands are reduced by 1 / 3 to 2 / 3;

[0099] Severe: The intrinsic glands are reduced by more than 2 / 3.

[0100] ③ Histopathological grading standard of intestinal metaplasia

[0101] Mild: Intestinal surface epithelium and / or glands account for less than 1 / 3 of the total length of the mucosa;

[0102] Moderate: Intestinal surface epithelium and / or glands occupy 1 / 3 to 2 / 3 of the total length of the mucosa;

[0103] Severe: The intestinal surface epithelium and / or glands occupy more than 2 / 3 of the total length of the mucosa.

[0104] ④ Pathological histological grading standard of dysplasia (atypical hyperplasia)

[0105] Mild: The nucleus is slightly larger, darker, round, oval or columnar, densely arranged, and located at the base of the cell. In the case of gastric type, the epithelial cells are columnar and the mucus secretion is reduced; in the case of intestinal type, the goblet cells are reduced and Paneth cells are rare. The glandular ducts are slightly proliferative, the lumen is slightly irregular, the arrangement is slightly disordered and the density is uneven.

[0106] Moderate: Cell atypia is more obvious. The nuclei are enlarged, oval or rod-shaped, of varying sizes, densely stained, arranged in a disordered and uneven manner, with a pseudostratified structure, and frequent nuclear divisions. The epithelial cells are columnar, mucus secretion is significantly reduced, goblet cells are rare, and Paneth cells are not seen. The glandular ducts are densely arranged, with tortuous branches, irregular luminal structures, and varying shapes and sizes.

[0107] Severe: Cell atypia is very obvious, sometimes difficult to distinguish from well-differentiated mucosal endothelial carcinoma. Epithelial cells are tall columnar (intestinal type), goblet cells and Paneth cells are absent; or they are cuboidal and amorphous (gastric type), and the mucus secretion function disappears. The cell nuclei are significantly enlarged, with different sizes and shapes, disordered and uneven arrangement, increased nuclear / cell ratio, dark staining or loose reticular, obvious nucleoli, and common mitotic figures. The glandular duct structure is obviously disordered, with extremely irregular shape, size and arrangement, and common budding, branching, papillae, common walls and back-to-back phenomena.

[0108] 2.2 TCM diagnostic criteria

[0109] Refer to the diagnostic criteria for gastric collateral blood stasis syndrome in the "Consensus on the Diagnosis and Treatment of Chronic Atrophic Gastritis with Integrated Traditional Chinese and Western Medicine" (2017).

[0110] According to TCM syndrome differentiation, it belongs to the syndrome of gastric meridian stasis. The main symptoms are: fullness or pain in the epigastric region. Secondary symptoms: ① stomach fullness or stomach pain that does not heal for a long time ② stomach pain that refuses to be pressed or pain like a needle piercing ③ dark complexion. Tongue and pulse: the tongue is dark red or has petechiae and ecchymosis; the pulse is stringy and astringent. The above requirements must include the main symptoms and tongue image, plus one or more secondary symptoms, and refer to the pulse image to make a diagnosis.

[0111] 3. Inclusion and exclusion criteria for clinical cases:

[0112] 3.1 Inclusion criteria

[0113] (1) Aged between 18 and 72 (inclusive);

[0114] (2) Patients diagnosed with CAG by gastroscopy and with pathological confirmation of IM and / or Dys;

[0115] (3) According to TCM syndrome differentiation, it belongs to gastric meridian stasis syndrome;

[0116] (4) The patient provides informed consent, has good compliance, and cooperates voluntarily.

[0117] 3.2 Exclusion criteria

[0118] (1) Patients with serious primary diseases of important organs such as heart, lung, brain, liver, and kidney;

[0119] (2) Patients with upper gastrointestinal bleeding;

[0120] (3) Those who take nonsteroidal anti-inflammatory drugs for a long time;

[0121] (4) Patients suspected of having malignant lesions;

[0122] (5) Pregnant and lactating women;

[0123] (6) People with mental disorders such as depression, anxiety, etc. and those with poor cooperation;

[0124] (7) Except for patients with severe dysplasia.

[0125] 3.3 Criteria for exclusion and dropout of cases

[0126] (1) The subject fails to comply with the medication, increases, decreases, or stops taking medication on his / her own, or takes medication that is prohibited in this study, which affects the determination of efficacy and safety;

[0127] (2) the subjects failed to adhere to regular follow-up;

[0128] (3) The subject voluntarily withdraws from the study.

[0129] 3.4 Case termination criteria

[0130] (1) During the trial, the subject's condition worsens and he is not suitable to continue the trial;

[0131] (2) The subject is no longer suitable for the trial due to comorbidities or complications or special physiological changes.

[0132] 3.5 Ethical review and signing of informed consent and commitment

[0133] The entire study complies with the Declaration of Helsinki and has been reviewed by the Ethics Committee. All patients need to understand the research methods and related precautions before enrolling for treatment, and are required to sign an informed consent and commitment letter.

[0134] 4 Efficacy criteria

[0135] Formulated with reference to the "Guidelines for Clinical Research of New Chinese Medicines" (Trial).

[0136] 4.1 TCM symptom efficacy evaluation criteria

[0137] ①Clinical recovery: symptoms and signs disappear or almost disappear, and symptom score decreases by ≥95%;

[0138] ② Significantly effective: symptoms and signs are significantly improved, and the symptom score is reduced by ≥70%;

[0139] ③Effective: symptoms and signs are improved, and the symptom score is reduced by ≥30%;

[0140] ④ Ineffective: There is no significant improvement in symptoms and signs, or even aggravation, and the symptom score is reduced by less than 30%.

[0141] Note: Calculation formula (Nimodipine method): [(pre-treatment score - post-treatment score) ÷ pre-treatment score] × 100%

[0142] Total effective rate = (cured + markedly effective + effective) ÷ total number of cases × 100%.

[0143] 4.2 Evaluation of the efficacy of TCM main symptoms

[0144] ①Clinical control: after the treatment, the symptoms disappear;

[0145] ② Significantly effective: after the treatment, the symptom grade is reduced by 2 levels;

[0146] ③ Effective: After the treatment, the symptom grade is reduced by 1 level;

[0147] ④ Invalid: Those who fail to meet the above standards.

[0148] 4.3 Evaluation criteria for gastroscopy efficacy

[0149] Under endoscopy, the mucosa of this disease is red and white, with white as the main color, flattened or even disappeared folds, exposed mucosal blood vessels, and mucosal granules or nodules. According to the CAG gastroscopy diagnostic criteria in the "Guidelines for Clinical Research of New Chinese Medicines" (Trial), the color, vascular transparency and texture of the gastric mucosa are mainly observed under endoscopy, and reasonable classification and grading quantitative standards are formulated. The integral method is used to compare the endoscopic efficacy before and after treatment.

[0150] 4.4 Pathological efficacy evaluation criteria

[0151] ① Recovery: Pathological histological examination confirmed that glandular atrophy, intestinal metaplasia and dysplasia returned to normal or disappeared.

[0152] ② Significantly effective: Pathological histological examination confirmed that glandular atrophy, intestinal metaplasia and dysplasia returned to normal or were alleviated by 2 grades.

[0153] ③Effective: Pathological histological examination confirmed that glandular atrophy, intestinal metaplasia and dysplasia were alleviated.

[0154] ④ Invalid: Failure to meet the above-mentioned effectiveness standards, or deterioration.

[0155] 4.5 Safety evaluation

[0156] Level 1 safety, no adverse reactions, and no abnormalities in safety index examinations;

[0157] Level 2 is relatively safe. If adverse reactions occur, no treatment is required and the medication can continue. There are no abnormalities in safety indicators and examinations.

[0158] Level 3: There are safety issues, moderate adverse reactions, or mild abnormalities in safety index tests. After treatment, the drug can continue to be administered;

[0159] Grade 4: The trial is terminated due to adverse reactions or obvious abnormalities in safety index examinations.

[0160] 5 Statistical methods

[0161] All data were entered into Excel and processed using SPSS25.0. Normality test was performed before processing. Chi-square test was used for count data, nonparametric rank sum test was used for rank data, t test was used for measurement data if it conformed to normal distribution, and nonparametric rank sum test was used if it did not conform to normal distribution. If P < 0.05, the difference was statistically significant.

[0162] 6 Treatment options

[0163] 6.1 Treatment

[0164] A total of 96 patients with gastric collateral stasis type PLGC who met the intake and excretion criteria were randomly divided into a treatment group (taking Weihe Huayu Pills) and a control group (taking Weifuchun), 48 cases in each group. The patients in the treatment group were given Weihe Huayu Pills orally, 3 times a day, 6g each time; the patients in the control group were treated with Weifuchun Capsules (produced by Hangzhou Huqingyutang Pharmaceutical Co., Ltd., National Medicine Standard Z20090697), 3 times a day, 4 capsules each time. The treatment course was 6 months, and clinical observation and data statistical analysis were performed.

[0165] 6.2 Observation indicators

[0166] 6.2.1 General indicators and safety observation indicators

[0167] Check once before taking the medicine and at the end of the 6th month of taking the medicine. General indicators include pulse, respiration, blood pressure, heart and lung auscultation, abdominal examination, etc.; safety observation indicators include blood routine, urine routine, stool routine + occult blood, liver function (ALT, AST), kidney function (BUN, Cr), electrocardiogram. Pay attention to possible adverse reactions and related indicator tests, and remind patients to regularly review relevant indicators and track them at any time if necessary.

[0168] 6.2.2 Efficacy observation indicators

[0169] (1) Gastroscopy

[0170] Check once before taking the medicine and at the end of the 6th month of taking the medicine. Refer to the CAG endoscopic diagnostic criteria in the "Consensus on the Diagnosis and Treatment of Chronic Atrophic Gastritis with Integrated Traditional Chinese and Western Medicine" (2017) and the "Guidelines for Clinical Research of New Chinese Medicines" (Trial), and mainly observe the color of the gastric mucosa, blood vessels, and mucosal texture (see Table 1). Note: According to the normal color of the mucosa, orange-red, red and white with red as the main color, red and white with white as the main color, pale or gray-white patches are scored as 0, 1, 2, and 3 points respectively, blood vessels are absent, reticular, and dendritic as 0, 1, and 2 points respectively, normal, thin, and disappeared mucosal folds are scored as 0, 1, and 2 points respectively, and the mucosal texture is smooth and soft, the mucosal texture is rough, and granular changes are scored as 0, 1, and 2 points respectively.

[0171] Table 1 Evaluation of mucosa under gastroscope

[0172]

[0173]

[0174] (2) Histopathological examination of gastric mucosa

[0175] Check once before taking the medicine and once at the end of the 6th month of taking the medicine. Refer to the CAG disease classification standards in the "Consensus on the Diagnosis and Treatment of Chronic Atrophic Gastritis with Integrated Traditional Chinese and Western Medicine" (2017) and the "Guidelines for Clinical Research of New Chinese Medicines". The changes in glandular atrophy, IM, and Dys were mainly observed and divided into four levels: none, mild, moderate, and severe (see Table 2). When taking samples, it should be noted that the site of gastric mucosal tissue taken at the end of the 6th month of taking the medicine should be kept consistent with the site before taking the medicine.

[0176] Table 2 Pathological evaluation

[0177]

[0178]

[0179] (3) Clinical symptoms

[0180] The main symptoms and signs were stomachache, pain in a fixed location, fullness in the stomach, refusal to press stomachache, poor appetite, belching and acid reflux, dry mouth and bitter taste, nausea and vomiting, dark complexion, constipation, dark red tongue or petechiae and ecchymosis on the tongue surface; stringy and astringent pulse, etc. The data were recorded once before taking the medicine, at the end of the third month of taking the medicine, and at the end of the sixth month of taking the medicine, for a total of 3 times. The TCM symptom classification and quantification were carried out in accordance with the "Guidelines for Clinical Research of New Chinese Medicines" (Trial). According to the symptoms of no, mild, moderate, and severe, the main symptoms were recorded as 0 points, 2 points, 4 points, and 6 points, respectively, and the secondary symptoms were recorded as 0 points, 1 point, 2 points, and 3 points. The tongue and pulse conditions were not scored (see Table 3).

[0181] Table 3 TCM symptom score table

[0182]

[0183]

[0184]

[0185] (4) Gastric function test

[0186] The patients were examined once before taking the medicine and once at the end of the sixth month of taking the medicine. On an empty stomach, 4 ml of venous blood was drawn and sent to the laboratory for testing. The changes of pepsinogen I (PG I), the ratio of pepsinogen I to pepsin II (PGII) PGR, and gastrin 17 (G-17) before and after treatment were observed.

[0187] 6.2.3 Hemorheology

[0188] The subjects were examined once before taking the medicine and at the end of the sixth month of taking the medicine. 4 ml of venous blood was drawn on an empty stomach and sent to the laboratory for testing.

[0189] 7. Treatment results

[0190] A total of 90 patients completed the trial as required, with 45 patients in the treatment group and 45 patients in the control group. After statistical analysis, the baseline data of the two groups, such as gender, age, and disease course, before treatment were basically the same and comparable (P>0.05).

[0191] 7.1 Total Effectiveness of Clinical Symptoms

[0192] After 6 months of medication, 2 cases in the treatment group were cured, 16 cases were significantly effective, 24 cases were effective, and 3 cases were ineffective, with an effective rate of 93.33%; in the control group, 0 cases were cured, 1 case was significantly effective, 34 cases were effective, and 10 cases were ineffective, with an effective rate of 77.78% (see Table 4).

[0193] Table 4 Total effective rate of Weihe Huayu Pills on clinical symptoms

[0194]

[0195] The chi-square test showed that the total effective rate of symptoms in the treatment group was 93.33%, and that in the control group was 77.78%, with a statistically significant difference (P<0.05).

[0196] 7.2 TCM symptom scores before and after treatment

[0197] Table 5 The scores of TCM symptoms before and after treatment with Weihe Huayu Pills

[0198]

[0199]

[0200] Note: Data are expressed as M(P 25 , P 75 ). Comparison of the treatment group before and after treatment * P<0.05, comparison between the control group after treatment and before treatment ▲ P<0.05.

[0201] 7.3 Distribution of gastric mucosal scores in patients before and after treatment

[0202] Table 6 Distribution of gastric mucosal scores in patients before and after treatment with Weihe Huayu Pills

[0203]

[0204]

[0205] Note: Comparison of treatment group after treatment and before treatment * P<0.05, comparison between the control group after treatment and before treatment ▲ P<0.05.

[0206] Before treatment, there was no significant difference in the distribution of mucosal color, vascular permeability, mucosal folds, and mucosal texture scores between the treatment group and the control group (P>0.05), which was comparable. After treatment, the number of patients with mucosal color of 0 points and 1 points increased, and the number of patients with 2 points and 3 points decreased; the number of patients with vascular permeability, mucosal folds, and mucosal texture of 0 points increased, and the number of patients with 1 point and 2 points decreased, and the above differences were statistically significant (P<0.05). After treatment, the distribution of mucosal color and mucosal texture scores of the two groups showed that the severity of the treatment group was lighter than that of the control group, and the difference was statistically significant (P<0.05); there was no significant difference in the distribution of vascular permeability and mucosal folds scores (P>0.05).

[0207] 7.4 Histopathological grading of gastric mucosa before and after treatment

[0208] Table 7 Effect of Weihe Huayu Pills on gastric mucosal pathological grading in patients before and after treatment

[0209]

[0210] Note: Comparison of treatment group after treatment and before treatment * P<0.05, comparison between the control group after treatment and before treatment ▲ P<0.05.

[0211] Before treatment, there was no significant difference in the grading of gastric mucosal glandular atrophy, intestinal metaplasia (IM), and dysplasia (Dys) between the treatment group and the control group (P>0.05), which was comparable. After treatment, the severity of glandular atrophy and IM in the two groups was improved compared with that before treatment (P<0.05), and there was no significant difference in Dys (P>0.05). After treatment, there was a significant difference in IM grading between the two groups (P<0.05), and there was no significant difference in glandular atrophy and Dys grading (P>0.05).

[0212] 7.5 Gastric function test results before and after treatment

[0213] Table 8 Gastric function test results of patients before and after treatment with Weihe Huayu Pills

[0214]

[0215] Note: Comparison of treatment group after treatment and before treatment * P<0.05, comparison between the control group after treatment and before treatment ▲ P<0.05.

[0216] There was no significant difference in PGI, PGR and G-17 levels between the two groups before treatment (P>0.05). After treatment, the PGI and PGR levels of the treatment group and the control group increased, and the G-17 level decreased compared with before treatment, with statistically significant differences (P<0.05). After treatment, the PGI and PGR levels of the treatment group were higher than those of the control group, and the G-17 level was lower (P<0.05), with statistically significant differences.

[0217] 7.6 Blood Rheology Test Results

[0218] Table 9 Blood rheology test results of patients before and after treatment with Weihe Huayu Pills

[0219]

[0220]

[0221] Note: Comparison of treatment group after treatment and before treatment * P<0.05, comparison between the control group after treatment and before treatment ▲ P<0.05.

[0222] Before treatment, there were no significant differences in whole blood low shear rate, whole blood high shear rate, plasma viscosity, whole blood reduced viscosity (low), whole blood reduced viscosity (high), red blood cell aggregation index, red blood cell rigidity index, and fibrinogen level between the two groups (P>0.05), and they were comparable. After treatment, the whole blood low shear rate, whole blood high shear rate, plasma viscosity, whole blood reduced viscosity (low), whole blood reduced viscosity (high), red blood cell aggregation index, red blood cell rigidity index, and fibrinogen level in the two groups were lower than those before treatment (P<0.05). After treatment, the whole blood low shear rate, whole blood high shear rate, plasma viscosity, whole blood reduced viscosity (low), whole blood reduced viscosity (high), red blood cell aggregation index, red blood cell rigidity index, and fibrinogen level in the treatment group were lower than those in the control group, and the difference was statistically significant (P<0.05).

[0223] 7.7 Safety indicator testing status

[0224] After treatment, no abnormalities related to medication were found in routine blood tests, liver function, kidney function, stool routine tests plus occult blood, urine routine tests, and electrocardiograms in both groups, which met safety standards.

[0225] 7.8 Conclusion

[0226] Weihe Huayu Pills can effectively relieve the symptoms of gastric collateral stasis in gastric precancerous lesions, improve the endoscopic gastric mucosal condition, block or even reverse the pathological changes of gastric mucosa, and regulate gastric function. Its mechanism may be that it improves blood rheology and reduces blood viscosity to play a therapeutic role in gastric precancerous lesions. Its clinical use is safe.

[0227] Typical cases:

[0228] Zhang XX, male, 71 years old, first diagnosed on July 6, 2022.

[0229] The patient came to our hospital with the main complaint of "stomach bloating and belching for 6 years, aggravated with stomach pain for 5 days". Current medical history: 6 years ago, there was no obvious cause for stomach bloating, belching, occasional acid reflux, and heartburn, which improved after intermittent use of Wei Fuchun and Chinese medicine decoctions. 5 days ago, there was no obvious cause for stomach bloating and belching, and stomach pain occurred. Self-medication could not relieve it, so he came to our hospital for treatment. Current symptoms: stomach bloating, belching, stabbing pain in the epigastric area that refuses to be pressed, occasional acid reflux and heartburn, palpitations, excessive flatulence, good appetite, poor sleep, good urination, constipation once every 3 days, dry stool. The tongue is dark red with thin white fur, and the pulse is thin, stringy and astringent. Gastroscopy showed: reflux esophagitis (LA-A), chronic atrophic gastritis; pathology showed: moderate atrophy and severe intestinal metaplasia of gastric antrum mucosa, mild to moderate dysplasia of some glands, mild atrophy and mild intestinal metaplasia of gastric body mucosa, and mild dysplasia of a small number of glands. Hp was negative. The gastroscopy report of this patient before treatment is shown in Figure 5 , pathological report before treatment is shown in Figure 7The diagnosis of traditional Chinese and Western medicine was consistent with PLGC gastric collateral stasis syndrome. There was no obvious abnormality in the general index and safety index examination, which met the inclusion requirements. The patient was selected into the treatment group by random number table method and was re-examined after taking Weihe Huayu Pills for 6 months.

[0230] Second visit (October 24, 2022): After taking the medicine for 3 months, the patient reported that his stomach bloating and belching were significantly relieved, stomach pain was relieved, the degree of refusal to press the pain was reduced, there was occasional acid reflux and heartburn, no panic, less flatulence, good appetite, frequent sleep, good urination, dry stool once a day. The tongue was slightly dark red with thin white fur, and the pulse was deep, thin, stringy and astringent. Continue to take Weihe Huayu Pills for another 3 months and then reexamine.

[0231] Third visit (February 17, 2023): The patient took the medicine for 6 months and reported that his stomach bloating and stomach pain disappeared, he occasionally had belching, acid reflux and heartburn, his flatulence returned to normal, his appetite was good, his sleep was normal, and his bowel movements were normal. The tongue was red with a thin white coating, and his pulse was thin and stringy. Gastroscopy prompts: Gastroscopy prompts: Reflux esophagitis (LA-A), chronic atrophic gastritis; pathological results: The gastric antrum showed mild atrophy and mild intestinal metaplasia, and the gastric body mucosa showed mild chronic inflammation. Hp negative. There were no obvious abnormalities in the reexamination of general indicators and safety indicators. The gastroscopy report of this patient after treatment is shown in Figure 6 , the pathological report after treatment is shown in Figure 8 .

[0232] The embodiments described above are only descriptions of the preferred modes of the present invention, and are not intended to limit the scope of the present invention. Without departing from the design spirit of the present invention, various modifications and improvements made to the technical solutions of the present invention by ordinary technicians in this field should all fall within the protection scope determined by the claims of the present invention.

Claims

1. A compound Chinese medicine for treating gastric precancerous lesions, It is characterized in that The compound Chinese medicine is composed of the following raw materials by weight: 5-15 parts of salvia miltiorrhiza, 3-10 parts of amomum villosum, 6-12 parts of atractylodes macrocephala, 3-12 parts of corydalis, 3-12 parts of magnolia bark, 3-15 parts of curcuma, 3-10 parts of pollen, 3-5 parts of centipede, 3-10 parts of honeycomb, 3-10 parts of soapberry, 9-30 parts of pseudoginseng, 15-60 parts of chicken gizzard lining and 15-60 parts of oldenlandia diffusa; The dosage form of the compound Chinese medicine is pills; the gastric precancerous lesions are gastric precancerous lesions of chronic atrophic gastritis of gastric collateral stasis type.

2. The compound Chinese medicine according to claim 1, It is characterized in that The compound Chinese medicine is composed of the following raw materials by weight: 12 parts of salvia miltiorrhiza, 10 parts of amomum villosum, 10 parts of atractylodes macrocephala, 12 parts of corydalis, 12 parts of magnolia bark, 10 parts of curcuma, 10 parts of pollen, 4 parts of centipede, 10 parts of honeycomb, 10 parts of soapberry, 15 parts of pseudostellaria, 15 parts of chicken gizzard lining and 15 parts of oldenlandia diffusa.

3. The compound Chinese medicine according to claim 1, It is characterized in that The pills are water pills or honey pills.

4. A method for preparing the compound Chinese medicine according to claim 1, It is characterized in that The steps include: The weighed raw materials are crushed into powder, the powder is made into granules by wet powder granulation and molding method, water is sprayed on the powder particles to moisten them, powder is sprinkled for absorption, the operation is repeated to obtain uniform pellets, and finally the pellets are covered, dried and coated; Alternatively, part of the weighed raw materials are crushed into powder, the powder is made into granules by wet powder granulation and molding method, the powder particles are sprayed with medicine juice made from the remaining raw materials to moisten them, and the powder is sprinkled for absorption, the operation is repeated to obtain uniform pellets, and finally the pellets are covered, dried and coated.

5. The preparation method according to claim 4, It is characterized in that The partial raw materials include pollen typhae, centipede, beehive, chicken gizzard lining and soapberry; the medicinal juice is the medicinal juice obtained by decocting salvia miltiorrhiza, amomum villosum, atractylodes macrocephala, corydalis yanhusuo, magnolia bark, zedoaria, pseudostellaria and oldenlandia diffusa.

6. A method for preparing the compound Chinese medicine according to claim 1, It is characterized in that The steps include: Weigh the raw materials, dry and crush them, mix the obtained powder with refined honey to adjust the medicine, roll them into strips, make them into pills, and package them.

7. The preparation method according to claim 6, It is characterized in that The mass ratio of the medicinal powder to the honey is 1:(1.2-1.5).